Carl Dambkowski Sells 5,500 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 5,500 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $134.17, for a total transaction of $737,935.00. Following the completion of the transaction, the insider owned 168,498 shares in the company, valued at $22,607,376.66. The trade was a 3.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, July 1st, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The stock was sold at an average price of $132.74, for a total transaction of $730,070.00.
• On Monday, June 22nd, Carl Dambkowski sold 26,400 shares of Apogee Therapeutics stock. The stock was sold at an average price of $132.60, for a total value of $3,500,640.00.
• On Wednesday, June 3rd, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The shares were sold at an average price of $78.71, for a total value of $432,905.00.

Apogee Therapeutics Stock Performance

NASDAQ APGE opened at $134.84 on Friday. Apogee Therapeutics Inc. has a fifty-two week low of $34.34 and a fifty-two week high of $134.88. The stock has a 50 day simple moving average of $119.35 and a two-hundred day simple moving average of $91.88. The stock has a market cap of $8.34 billion, a P/E ratio of -31.14 and a beta of 0.34.

Apogee Therapeutics (NASDAQ:APGE) last posted its earnings results on Monday, May 11th. The company reported ($1.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.01. Sell-side analysts predict that Apogee Therapeutics Inc. will post -4.45 earnings per share for the current year.

Institutional Trading of Apogee Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of APGE. Rockefeller Capital Management L.P. purchased a new position in Apogee Therapeutics in the fourth quarter worth about $25,000. Los Angeles Capital Management LLC purchased a new stake in shares of Apogee Therapeutics during the fourth quarter valued at approximately $37,000. GAMMA Investing LLC increased its position in shares of Apogee Therapeutics by 40.5% during the second quarter. GAMMA Investing LLC now owns 309 shares of the company’s stock valued at $41,000 after acquiring an additional 89 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Apogee Therapeutics by 61.7% during the first quarter. EverSource Wealth Advisors LLC now owns 645 shares of the company’s stock valued at $54,000 after acquiring an additional 246 shares in the last quarter. Finally, Longfellow Investment Management Co. LLC purchased a new position in Apogee Therapeutics in the 2nd quarter worth approximately $81,000. 79.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

APGE has been the subject of several research analyst reports. The Goldman Sachs Group set a $89.00 target price on shares of Apogee Therapeutics in a research report on Thursday, May 28th. Rothschild & Co Redburn initiated coverage on shares of Apogee Therapeutics in a research note on Friday, May 1st. They issued a “buy” rating and a $140.00 price target for the company. UBS Group lowered shares of Apogee Therapeutics from a “buy” rating to a “neutral” rating and raised their price objective for the stock from $100.00 to $135.11 in a report on Tuesday, June 23rd. Citigroup cut Apogee Therapeutics from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $125.00 to $135.00 in a research report on Tuesday, June 23rd. Finally, TD Cowen downgraded Apogee Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 23rd. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Apogee Therapeutics has a consensus rating of “Hold” and a consensus target price of $121.25.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.